INHX Inhibitex, Inc. (MM)

Today, www.BollingerReport.com introduced featured coverage of Inhibitex, Inc. (NASDAQ: INHX) and Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX). Full research reports are available to readers at: www.BollingerReport.com/index.php?sm1=INHX&sm2=IDIX.

Economic fundamentals leading into 2012 have set a generally positive pace with GDP growth likely to pick up through the coming year. However, there are several important caveats to note as the world economy continues to face headwinds and risks weigh to the downside. Positive outlooks are conditional on fiscal policy in payroll taxes and unemployment insurance benefits and upon the easing of the European debt situation. A repeat of volatility experienced in 2011 is likely in 2012, as perceptions about the strength of the U.S. economy and the euro zone will vary over time as events unfold.

Despite the current situation, our team continues to identify high momentum situations with growth potential -- there remains strong opportunity within careful discretion.

Bollinger Report screened and selected Inhibitex, Inc. for its current position within the healthcare industry. Inhibitex, Inc.is a biopharmaceutical company focused on the development of differentiated anti-infective products to prevent or treat serious infections. A copy of this report featuring Inhibitex, Inc. (NASDAQ: INHX) is available at: www.BollingerReport.com/index.php?sm1=INHX.

Bollinger Report is featuring Idenix Pharmaceuticals, Inc. for its changing role within the healthcare industry. Idenix Pharmaceuticals, Inc. (Idenix) is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and Europe. The Company's research and development focus is on the treatment of hepatitis C virus (HCV). To download researches and analysis on Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX) we welcome investors to visit: www.BollingerReport.com/index.php?sm2=IDIX.

About Bollinger Report Bollinger Report has come to be known among its peers as a trusted source of information for both investors and technical traders. Our online content is continually updated, bringing fresh new researches and analyses to the investment community.

Contact: Martin Schwartz Email Contact www.BollingerReport.com